Cu
Curocell
Seoul KRFounded 201750 employees
Private CapbiotechPrivateOncology
Platform: CAR-NK
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Rimasotorasib | CUR-6593 | Phase 1 | 2 | AuroraA | SLEHNSCC | ||
| Nidainavolisib | CUR-4378 | Approved | 3 | Menin | WilmsPSP | ||
| CUR-8000 | CUR-8000 | Phase 2 | 2 | Aβ | Ewing SarcomaRSV | ||
| Lisosacituzumab | CUR-6038 | Phase 1/2 | 2 | LAG-3 | PompeFTD |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)